Skip to content
DataLookout
Menu

PearlNCT07827807

PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Notable Start date pushed from Sep 30, 2026 to Nov 30, 2026
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

1-year progression-free survival (PFS) by mRECIST
Timeframe: 1 year after start of study treatment

Secondary (8)

1-year overall survival (OS)
Objective response rate (ORR) by mRECIST
Objective response rate (ORR) by RECIST v1.1
Disease control rate (DCR) by mRECIST
Disease control rate (DCR) by RECIST v1.1
Show 3 moreShow less
Duration of response (DOR) by mRECIST
Incidence of hepatic decompensation
Incidence of treatment-emergent adverse events

Arms and interventions

Partial TACE Enhancing Anti-tumor Response with Lenvatinib in unresectable HCCExperimental

Lenvatinib: Oral administration at 12 mg once daily (body weight ≥ 60 kg) or 8 mg once daily (body weight \< 60 kg). Treatment continues until disease progression, unacceptable toxicity, or patient withdrawal. Partial TACE: Performed within 4 weeks after starting lenvatinib.

Drugs: Lenvatinib

Procedures: Partial transarterial chemoembolization (TACE)